WO2007134118A3 - Composition à base de protéines et méthodes d'utilisation - Google Patents

Composition à base de protéines et méthodes d'utilisation Download PDF

Info

Publication number
WO2007134118A3
WO2007134118A3 PCT/US2007/068585 US2007068585W WO2007134118A3 WO 2007134118 A3 WO2007134118 A3 WO 2007134118A3 US 2007068585 W US2007068585 W US 2007068585W WO 2007134118 A3 WO2007134118 A3 WO 2007134118A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
same
based composition
protein based
compositions
Prior art date
Application number
PCT/US2007/068585
Other languages
English (en)
Other versions
WO2007134118A2 (fr
Inventor
Chulso Moon
Original Assignee
Chulso Moon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chulso Moon filed Critical Chulso Moon
Publication of WO2007134118A2 publication Critical patent/WO2007134118A2/fr
Publication of WO2007134118A3 publication Critical patent/WO2007134118A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne, dans divers modes de réalisation, des compositions pharmaceutiques comprenant une ou plusieurs protéines réticulées et un ou plusieurs principes actifs, ainsi que des méthodes d'élaboration de telles compositions, et des méthodes d'utilisation de telles compositions dans le traitement de divers troubles et maladies.
PCT/US2007/068585 2006-05-09 2007-05-09 Composition à base de protéines et méthodes d'utilisation WO2007134118A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79871706P 2006-05-09 2006-05-09
US60/798,717 2006-05-09

Publications (2)

Publication Number Publication Date
WO2007134118A2 WO2007134118A2 (fr) 2007-11-22
WO2007134118A3 true WO2007134118A3 (fr) 2009-09-11

Family

ID=38694679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/068585 WO2007134118A2 (fr) 2006-05-09 2007-05-09 Composition à base de protéines et méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2007134118A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017664B2 (en) 2006-12-15 2015-04-28 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487206A3 (fr) 2008-06-18 2012-11-28 Lifebond Ltd Compositions réticulables à base de gélatine
JP5796860B2 (ja) 2009-12-22 2015-10-21 ライフボンド リミテッドＬｉｆｅｂｏｎｄ Ｌｔｄ 架橋マトリックスの特性を調節するための酵素的架橋剤の改変
CA2807012A1 (fr) 2010-08-05 2012-02-09 Lifebond Ltd. Pansements et adhesifs contenant des compositions seches
US10265413B2 (en) 2014-11-05 2019-04-23 University Of The Sciences In Philadelphia High molecular weight biodegradable gelatin-doxorubicin conjugate
CN113559051B (zh) * 2021-07-29 2023-06-23 北京赛升药业股份有限公司 一种可注射明胶载药缓释体系及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034925A1 (en) * 2004-04-02 2006-02-16 Au Jessie L Tumor targeting drug-loaded particles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034925A1 (en) * 2004-04-02 2006-02-16 Au Jessie L Tumor targeting drug-loaded particles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017664B2 (en) 2006-12-15 2015-04-28 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants

Also Published As

Publication number Publication date
WO2007134118A2 (fr) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2005055944A3 (fr) Composition d&#39;oligosaccharides et leur utilisation dans le traitement d&#39;infection
MY143795A (en) Tetrahydropyridoindole derivatives
WO2005116025A3 (fr) Composes
WO2006060680A3 (fr) Variants de la proteine mda-7 presentant une activite antiproliferative
WO2007006307A3 (fr) Nouveaux sels de monoalkylesters d&#39;acide fumarique et leur utilisation pharmaceutique
WO2006124748A3 (fr) Composes polycycliques et procedes pour les utiliser
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d&#39;utilisation
WO2006003388A8 (fr) Compositions et procedes pour le traitement de troubles inflammatoires
EP2537849A3 (fr) Azaindoles utiles en tant qu&#39;inhibiteurs des kinases Janus
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2005077093A3 (fr) Fabrication d&#39;enzymes lysosomales hautement phosphorylees et utilisations associees
WO2006013441A3 (fr) Utilisation de bacteries probiotiques dans la preparation de compositions topiques destinees a la protection de la peau
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2005105780A3 (fr) Compositions utiles en tant qu&#39;inhibiteurs de la rock et d&#39;autres proteines kinases
WO2007035716A3 (fr) Compositions de proteines rap specifiques des proteines contenant du cr, et leurs utilisations
WO2008036932A3 (fr) Compositions et procédés utilisant l&#39;espèce boswellia
WO2007127273A3 (fr) Procédés et compositions permettant de modifier la fonction cellulaire
WO2010130832A3 (fr) Séquences d&#39;acides aminés dirigées contre dickkopf-1 et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies associées à la déperdition osseuse et/ou à l&#39;ostéolyse
WO2007002836A3 (fr) Procedes et compositions pour la prevention et le traitement de maladie renale
WO2006015258A3 (fr) Procedes et compositions associes aux proteines argonautes
WO2007100555A3 (fr) Compositions contenant de la lactoferrine et leurs procédés d&#39;utilisation pour favoriser la croissance de cellules cutanées
WO2007125105A3 (fr) Activateurs de la glucokinase benzamidique
WO2008116139A3 (fr) Composés utiles en tant qu&#39;inhibiteurs des kinases de janus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07783533

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07783533

Country of ref document: EP

Kind code of ref document: A2